相关实验视频

Updated: Jun 23, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

探索肺腺癌中CD73的表达与EGFR基因组改变

Elodie Long-Mira^1,2, Christophe Bontoux¹, Guylène Rignol^1,2

¹Laboratory of Clinical and Experimental Pathology, IHU RespirERA, Biobank Côte d'Azur BB-0033-00025, FHU OncoAge, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.

|March 28, 2025

概括

在EGFR突变肺腺癌中CD73的表达有所不同,可以预测治疗反应. 向CD73可能为这些患者提供新的治疗策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

免疫检查点抑制剂 (ICI) 由于免疫抑制瘤微环境 (TME),在具有EGFR突变 (EGFRm) 的晚期肺腺癌 (LUAD) 中具有有限的疗效.
EGFRm LUAD患者经常面临ICI的毒性增加.
CD73是一种通过腺生产促进免疫逃避的酶,是潜在的治疗点.

研究的目的:

为了研究带有EGFR变异的LUAD中的CD73表达.
为了确定CD73表达的临床病理相关性.

主要方法:

免疫组织化学 (IHC) 在76名未经治疗的LUAD患者中评估了CD73表达在瘤细胞 (CD73TC) 和树皮细胞 (CD73SC) 中.
PD-L1表达也通过IHC进行了评估.
使用分子测序和FISH识别了EGFR变异;基于CD73TC表达的无事件生存率 (EFS) 进行了分析.

主要成果:

在66%的病例中发现了CD73TC表达,高表达与改善的EFS相关 (p=0.045).
CD73TC和PD-L1表达没有显著的相关性.
在18%的病例中检测到CD73SC表达,与早期,PD-L1阴性和非EGFR放大瘤相关.

结论:

在EGFRm LUAD中CD73表达异质,并与各种TME配置文件相关.
这些发现表明CD73作为EGFRm LUAD治疗向的预测生物标志物的潜力.
在这种患者群体中,CD73代表了临床相关的标.

关键词:

CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 欧洲农业基金会 (EGFR) 是一个基金.在PD-L1中.免疫组织化学免疫组织化学免疫疗法免疫疗法肺部腺癌的癌症.非小细胞肺癌的肺癌.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...